Anthropometric Measurements as Predictors of Low Birth Weight Among Tanzanian Neonates: A Hospital-Based Study
November 7, 2025
Free CME credits
Both our subscription plans include Free CME/CPD AMA PRA Category 1 credits.
Brand Name :
Unituxin
(United States) [Available]Synonyms :
dinutuximab
Class :
Antineoplastics and Monoclonal Antibody
Brand Name :
Unituxin
(United States) [Available]Synonyms :
dinutuximab
Class :
Antineoplastics and Monoclonal Antibody
Dosage Forms & Strengths
solution for injection
17.5mg/5ml (3.5mg/ml)
17.5 mg per m2 per day given IV over 10-20hrs for four days of 5 cycles:
on 4, 5, 6, and 7 days infuse cycles 1, 3, and 5
cycles and 1, 3, and 5 cycles are 24 days in duration
On 8, 9, 10, and 11 days infuse during cycles 2 and 4
cycles 2 and 4 are 32 days in duration
Rate of Infusion:
Initiate 0.875 mg per m2 per hour for 30 minutes
Gradually increase the dose to 1.75 mg per m2 per hour
Dose Adjustments
Renal Dose Adjustments:
No Data available
Liver Dose Adjustments:
No Data available
when both drugs are combined, there may be an increased risk or severity of adverse effects
when both drugs are combined, there may be an increased risk or severity of infection
when both drugs are combined, there may be an increased risk or severity of adverse effects
may increase the risk of adverse effects when combined
when both drugs are combined, there may be an increased risk or severity of adverse effects
when both drugs are combined, there may be an increased risk or severity of adverse effects
when both drugs are combined, there may be an increased risk or severity of adverse effects
when both drugs are combined, there may be an increased risk or severity of adverse effects
when both drugs are combined, there may be an increased risk or severity of adverse effects
when both drugs are combined, there may be an increased risk or severity of adverse effects
when both drugs are combined, there may be an increased risk or severity of adverse effects
when both drugs are combined, there may be an increased risk or severity of adverse effects
when both drugs are combined, there may be an increased risk or severity of adverse effects
when both drugs are combined, there may be an increased risk or severity of adverse effects
It may diminish the effects when combined with rozanolixizumab by receptor binding competition
When mometasone furoate is used together with dinutuximab, this leads to enhanced risk or seriousness of adverse outcomes
When dinutuximab is used together with andrographolide, this leads to enhanced risk or seriousness of bleeding
With very limited expression on healthy tissues, dinutuximab is an IgG1 monoclonal human/mouse chimeric antibody that targets GD2, which includes human neuroblastoma and melanoma.
It consists of the constant sections of human IgG1 heavy-chain and kappa light-chain as well as the variable heavy- and light-chain regions of the murine anti-GD2 mAb.
Dinutiximab causes tumor cells to become cytotoxic both complement-dependently and antibody-dependently, which stops the tumor from growing and causes apoptosis.
Adverse drug reactions:
Frequency defined
>10%
Pain
Thrombocytopenia
Lymphopenia
Diarrhea
Capillary leak syndrome
Neutropenia
Urticaria
Hypoalbuminemia
Hypoxia
Hypophosphatemia
Tachycardia
Hyperglycemia
Sepsis
Pyrexia
Hemorrhage
Hypertriglyceridemia
Device related infection
Proteinuria
Increased serum creatinine
Decreased appetite
In 26% of cases, patients experienced serious and potentially fatal infusion responses.
Before every dinutuximab infusion, give the necessary premedication.
After every dinutuximab infusion, keep a cautious eye out for any indications of an infusion reaction for at least four hours.
Intravenous opioid should be given before, throughout, and for two hours after the infusion is finished.
In 2-9% of patients with high-risk neuroblastoma in clinical trials, grade 3 peripheral sensory neuropathy developed.
Contraindication:
Hypersensitivity
Caution:
Neuropathic pain
Infusion-related reactions
Capillary Leak Syndrome
Hypotension
Pregnancy warnings:
Breastfeeding warnings:
Pregnancy Categories:
Dinutuximab attaches to neuroblastoma tumor cells in vitro and uses complement-mediated and cell-mediated cytotoxicity to cause tumor cell lysis.
It activates Complement-Dependent Cytotoxicity through initiation of the classical complement cascade.
It engages natural killer (NK) cells to promote antibody-dependent cell-mediated cytotoxicity (ADCC).
Examine the solution visually for particulate matter and discoloration before administration. Throw away any cloudy, noticeably discoloured, or particle-containing solutions.
The necessary volume should be aseptically removed from the single-use vial and injected into a 100 mL bag of 0.9% NaCl.
Before starting each dosage, make sure the patient has sufficient hematologic, respiratory, hepatic, and renal function.
Not to be administered as a bolus or IV push.
Start with a 30-minute infusion rate of 0.875 mg/m2/hour.
Patient information leaflet
Generic Name: dinutuximab
Why do we use dinutuximab?
For the treatment of pediatric patients with high-risk neuroblastoma, dinutuximab is recommended in conjunction with granulocyte-macrophage colony-stimulating factor (GM-CSF), interleukin-2 (IL-2), and 13-cis-retinoic acid (RA).
High-risk neuroblastoma usually in children in individuals who have at least a partial response or minimal residual illness following standard multimodal therapy.
Both our subscription plans include Free CME/CPD AMA PRA Category 1 credits.
On course completion, you will receive a full-sized presentation quality digital certificate.
A dynamic medical simulation platform designed to train healthcare professionals and students to effectively run code situations through an immersive hands-on experience in a live, interactive 3D environment.
When you have your licenses, certificates and CMEs in one place, it's easier to track your career growth. You can easily share these with hospitals as well, using your medtigo app.
